— Know what they know.
Not Investment Advice

BNKL OTC

Bionik Laboratories Corp.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -100.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Care Facilities · Tech Score Neutral · Power 49 · $1248 mcap · 735726 float · 0.072% daily turnover

Balance Sheet Trends

Total Assets
$3M -28.1% ▼
5Y CAGR: -34.8%
Total Liabilities
$5M +186.1% ▲
5Y CAGR: -9.2%
Shareholders Equity
-$2M -156.0% ▼
Cash & Investments
$427K -78.5% ▼
5Y CAGR: -3.4%
Total Debt
$2M +0.0% ▲
5Y CAGR: +115.9%
Net Debt
$2M +199.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$447K$2M$608K$2M$427K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$447K$2M$608K$2M$427K
Net Receivables$2M$865K$452K$275K$453K
Inventory$406K$1M$692K$1M$1M
Other Current Assets$0$0$0$0$0
Total Current Assets$4M$6M$3M$5M$3M
Property, Plant & Equip.$193K$154K$94K$91K$442K
Goodwill & Intangibles$27M$13M$5M$0$134K
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets-$27M$0$0$0$9K
Total Non-Current Assets$27M$13M$5M$91K$585K
Total Assets$31M$19M$9M$5M$3M
— Liabilities —
Accounts Payable$1M$857K$455K$305K$558K
Short-Term Debt$0$2M$3M$0$0
Deferred Revenue$468K$616K$268K$314K$342K
Other Current Liabilities$0$0$46K$276K$291K
Total Current Liabilities$3M$5M$4M$1M$2M
Long-Term Debt$0$0$1M$0$2M
Other Non-Current Liab.$0$0$304K$0$0
Total Non-Current Liabilities$0$416K$1M$257K$3M
Total Liabilities$3M$5M$6M$2M$5M
— Equity —
Common Stock$4K$5K$6K$7K$7K
Retained Earnings-$46M-$71M-$85M-$95M-$100M
Accumulated OCI$42K$42K$42K$28K$30K
Total Stockholders Equity$27M$13M$3M$3M-$2M
Total Liabilities & Equity$31M$19M$9M$5M$3M
— Key Metrics —
Total Debt$0$2M$4M$0$2M
Net Debt-$447K-$191K$3M-$2M$2M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms